A new jab to treat Alzheimer's disease by halting its progression has been developed by researchers in the UK, it has been revealed.
Following a three-month trial of five patients, it was understood that no deterioration was recorded, with subjects maintaining a stable and healthy condition.
Professor Mark Pepys of University College London, the leading institution in this new research, told the Daily Mail that new drug CPHPC was able to remove a protein in the bloodstream which usually contributes to the build-up of plaques in the brain, in turn making Alzheimer's disease conditions worse.
He continued: "The best drugs at the moment slow progression by perhaps five per cent in the first six months.
"If our drug did as much as that, it would be wonderful. If it did more than that, it would be significant."
Alzheimer's Society is the major charity dealing with people suffering from the condition, which affects around 700,000 across the UK at the moment.
Please click here for advice to help you find the right type of care.